Effectiveness of first-line ET plus CDK4/6i in patients with HR+/HER2− aBC worsens progressively with decreasing ERα expression, and PgR expression adds further prognostic discrimination, with low ERα and PgR expression identifying a subgroup of patients with particularly poor outcomes.
F. Ligorio, L. Provenzano, R. Caputo et al.· EClinicalMedicine· 0 citations
An appraisal of the clinical utility of genomic tests, particularly OncotypeDX®, aims to reinforce their fundamental role in personalizing adjuvant treatment decisions and optimizing resource allocation, while emphasizing the need for further research to address remaining uncertainties.
M. Dieci, P. Conte, D. Generali et al.· International Journal of Bio...· 0 citations
While advanced-stage BC often presents an immunosuppressive tumor microenvironment that hinders vaccine efficacy, early-stage disease offers a more favorable immunological milieu for inducing robust and durable T-cell responses.
A. Caltavituro, C. Martinelli, M. Palleschi et al.· Journal of Experimental &...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.